1. Home
  2. FFIN vs RYTM Comparison

FFIN vs RYTM Comparison

Compare FFIN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FFIN
  • RYTM
  • Stock Information
  • Founded
  • FFIN 1890
  • RYTM 2008
  • Country
  • FFIN United States
  • RYTM United States
  • Employees
  • FFIN N/A
  • RYTM N/A
  • Industry
  • FFIN Major Banks
  • RYTM Biotechnology: Pharmaceutical Preparations
  • Sector
  • FFIN Finance
  • RYTM Health Care
  • Exchange
  • FFIN Nasdaq
  • RYTM Nasdaq
  • Market Cap
  • FFIN 5.3B
  • RYTM 5.9B
  • IPO Year
  • FFIN N/A
  • RYTM 2017
  • Fundamental
  • Price
  • FFIN $35.38
  • RYTM $97.61
  • Analyst Decision
  • FFIN Hold
  • RYTM Strong Buy
  • Analyst Count
  • FFIN 4
  • RYTM 13
  • Target Price
  • FFIN $39.50
  • RYTM $101.92
  • AVG Volume (30 Days)
  • FFIN 590.6K
  • RYTM 579.7K
  • Earning Date
  • FFIN 10-16-2025
  • RYTM 08-05-2025
  • Dividend Yield
  • FFIN 2.15%
  • RYTM N/A
  • EPS Growth
  • FFIN 21.27
  • RYTM N/A
  • EPS
  • FFIN 1.71
  • RYTM N/A
  • Revenue
  • FFIN $578,401,000.00
  • RYTM $156,287,000.00
  • Revenue This Year
  • FFIN $20.88
  • RYTM $37.86
  • Revenue Next Year
  • FFIN $5.94
  • RYTM $72.72
  • P/E Ratio
  • FFIN $20.69
  • RYTM N/A
  • Revenue Growth
  • FFIN 16.40
  • RYTM 53.55
  • 52 Week Low
  • FFIN $30.58
  • RYTM $43.57
  • 52 Week High
  • FFIN $44.66
  • RYTM $99.04
  • Technical
  • Relative Strength Index (RSI)
  • FFIN 49.28
  • RYTM 73.48
  • Support Level
  • FFIN $33.52
  • RYTM $95.30
  • Resistance Level
  • FFIN $34.50
  • RYTM $99.04
  • Average True Range (ATR)
  • FFIN 1.01
  • RYTM 3.21
  • MACD
  • FFIN 0.14
  • RYTM 0.20
  • Stochastic Oscillator
  • FFIN 56.71
  • RYTM 90.50

About FFIN First Financial Bankshares Inc.

First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto. It derives maximum revenue from Construction and Development Segment.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Share on Social Networks: